Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 66,123 |
|
|||||
| News | - | ||||||
| Day High | 0.444 | Low High |
|||||
| Day Low | 0.418 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| GRI Bio Inc | GRI | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.0159 | 3.75% | 0.44 | 18:29:09 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.43 | 0.418 | 0.444 | 0.429 | 0.4241 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 148 | 66,123 | US$ 0.4275521 | US$ 28,271 | - | 0.41 - 62.2314 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 16:45:50 | 9 | US$ 0.4253 | USD |
GRI Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 1.41M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
GRI Bio News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GRI Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.4243 | 0.462 | 0.41 | 0.4280512 | 58,586 | 0.0157 | 3.70% |
| 1 Month | 0.5373 | 0.59 | 0.41 | 0.4952618 | 114,283 | -0.0973 | -18.11% |
| 3 Months | 1.15 | 1.62 | 0.41 | 0.8362408 | 333,115 | -0.71 | -61.74% |
| 6 Months | 8.33 | 10.36 | 0.41 | 2.59 | 607,144 | -7.89 | -94.72% |
| 1 Year | 57.40 | 62.2314 | 0.41 | 3.85 | 339,543 | -56.96 | -99.23% |
| 3 Years | 92.40 | 93.31 | 0.41 | 4.25 | 334,318 | -91.96 | -99.52% |
| 5 Years | 92.40 | 93.31 | 0.41 | 4.25 | 334,318 | -91.96 | -99.52% |
GRI Bio Description
| GRI Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a pipeline of Natural Killer T (NKT) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases. The Company's lead program, GRI-0621 is a small molecule RAR-beta dual agonist that inhibits the activity of human Type I, or invariant, NKT (iNKT) cells, which is being developed for the treatment of Idiopathic pulmonary fibrosis (IPF). GRI-0621 is a once-daily oral capsule for several fibrotic indications. The Company¿s second asset GRI-0803, is a novel activator of human Type 2 NKT cells in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus. Additionally, the Company has a library of 500+ proprietary compounds targeting a number of high value indications with unmet need. |
